Estimating Prevalence of Inherited Disorders of Sulfur Amino Acids Metabolism in Patients With Psychotic Disorders.

Last updated: May 31, 2024
Sponsor: University Hospital, Grenoble
Overall Status: Active - Recruiting

Phase

N/A

Condition

Schizotypal Personality Disorder (Spd)

Tourette's Syndrome

Schizophrenia And Schizoaffective Disorders (Pediatric)

Treatment

Sulfitest

Clinical Study ID

NCT05206292
38RC21.0294
2021-A01940-41
  • Ages > 18
  • All Genders

Study Summary

Screening for sulfur amino acid metabolism pathologies using a sulfitest in adult patients with psychotic disorder.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female 18 years of age and older,

  • Followed for a psychotic disorder,

  • With no known organic etiology for the psychotic disorder,

  • Not having formulated its opposition to participation in the study (or his/hertutor/curator),

  • Affiliated with the social security system.

Exclusion

Exclusion Criteria:

  • Patients protected by law (minors, pregnant or breastfeeding women, deprived ofliberty or hospitalized under constraint, under administrative or judicialsupervision) except patients under tutorship or curatorship.

Study Design

Total Participants: 600
Treatment Group(s): 1
Primary Treatment: Sulfitest
Phase:
Study Start date:
January 12, 2023
Estimated Completion Date:
June 01, 2025

Study Description

Psychotic disorder is a public health problem, with a cumulative incidence in the general population estimated at 3%. Although in most cases the origin is purely psychiatric, psychotic disorder can also represent a mode of entry into many organic pathologies. Among these, hereditary metabolic diseases, although rare in the general population, hold a special place, especially in view of their potentially treatable character. However, the identification of this type of disease within the mass of patients with psychotic disorders can be an extremely complex task, and has been the subject of scientific interest for many years.

Recently, at the Grenoble Alpes University Hospital, a new hereditary metabolic disease that causes psychotic disorders has been discovered. This disease was identified in a family of patients, most of whom had psychotic disorders, and all of whom had deep cystic leukoencephalopathy on MRI and a positive sulfitest. The discovery of this new hereditary metabolic disease raises the question of its prevalence in patients with psychotic disorders, and more generally of the prevalence of diseases of sulfur amino acid metabolism.

PsyNIT study therefore aims, using the sulfitest, to detect hereditary diseases of sulfur amino acid metabolism in a sample of patients with psychotic disorders without known organic etiology. The discovery of other patients would raise the question of screening more widely for this type of pathology, and would modify the management of the patients thus screened in terms of follow-up and possibly treatment.

Connect with a study center

  • CHU Grenoble Alpes

    Grenoble, 38043
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.